Precision Biosciences (DTIL) director gains 21,000 shares as RSUs vest into common stock

Rhea-AI Filing Summary

PRECISION BIOSCIENCES INC director Kevin Buehler reported the vesting and settlement of restricted stock units into common shares. On May 20, 2026, 21,000 RSUs converted into 21,000 shares of common stock at no cash exercise price. These RSUs were granted on June 3, 2025 and vested based on continued service. Following this equity award vesting, Buehler directly owns 49,137 shares of common stock and did not report any share sales in this filing.

Insider Trade Summary

21,000 shares exercised/converted

Mixed 2 txns

Insider Buehler Kevin

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	21,000	$0.00	--
Exercise	Common Stock	21,000	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 49,137 shares (Direct, null)

Footnotes (1)

1. Represents the vesting of Restricted Stock Units ("RSUs") on May 20, 2026. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. On June 3, 2025 the Reporting person was granted RSUs. The RSUs vested on the earlier to occur of (i) June 3, 2026 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Key Figures

RSUs vested: 21,000 units Common shares acquired from RSUs: 21,000 shares Shares held after transaction: 49,137 shares +3 more

6 metrics

RSUs vested 21,000 units Converted into common stock on May 20, 2026

Common shares acquired from RSUs 21,000 shares Settlement of RSUs into common stock

Shares held after transaction 49,137 shares Director’s direct common stock ownership following RSU vesting

Exercise price per RSU $0.0000 per share RSUs converted to common stock at no cash exercise cost

RSU grant date June 3, 2025 Original grant date for the 21,000 RSUs

RSU vesting date May 20, 2026 Date RSUs vested and settled into common stock

Key Terms

Restricted Stock Units, RSUs, derivative security

3 terms

Restricted Stock Units financial

"Represents the vesting of Restricted Stock Units ("RSUs") on May 20, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

derivative security financial

"Transaction code M is described as an exercise or conversion of derivative security."

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Buehler Kevin

(Last) (First) (Middle)

C/O PRECISION BIOSCIENCES, INC.

302 E. PETTIGREW ST, SUITE A-100

(Street)

DURHAM NORTH CAROLINA 27701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/20/2026		M		21,000(1)	A	(2)	49,137	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	05/20/2026		M			21,000	(3)	(3)	Common Stock	21,000	$0	0	D

Explanation of Responses:

1. Represents the vesting of Restricted Stock Units ("RSUs") on May 20, 2026.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. On June 3, 2025 the Reporting person was granted RSUs. The RSUs vested on the earlier to occur of (i) June 3, 2026 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Remarks:

	/s/ Dario Scimeca, Attorney-in-Fact for Kevin Buehler	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did DTIL director Kevin Buehler report?

Director Kevin Buehler reported the vesting and conversion of 21,000 restricted stock units into common stock. The RSUs settled on May 20, 2026, increasing his direct common share holdings without any reported share sales in this Form 4.

How many Precision Biosciences (DTIL) shares does Kevin Buehler hold after this Form 4?

After the reported RSU vesting, Kevin Buehler directly holds 49,137 shares of Precision Biosciences common stock. This reflects the addition of 21,000 shares from vested RSUs and no sales disclosed in this filing.

Were any Precision Biosciences (DTIL) shares sold in this Form 4 filing?

No sales were reported in this Form 4. The transactions reflect only the vesting and settlement of 21,000 restricted stock units into common shares, with no open-market or other dispositions disclosed in the filing.

What are restricted stock units (RSUs) in the context of DTIL’s Form 4?

In this Form 4, restricted stock units represent a contingent right to receive one share of Precision Biosciences common stock per unit. The 21,000 RSUs vested on May 20, 2026, based on Buehler’s continued service, and then converted into common shares.

When were the DTIL RSUs granted and when did they vest for Kevin Buehler?

The RSUs were granted on June 3, 2025 and vested on May 20, 2026. Vesting occurred on the earlier of June 3, 2026 or the day before the next annual stockholder meeting, subject to Buehler’s continued service.